HAGGERTY POLICY SOLUTIONS for AMGEN
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEANNE HAGGERTY New | — |
Budget/Appropriations BUD
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEANNE HAGGERTY New | — |
Health Issues HCR
S. 1943, the Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 5376, Build Back Better Act (prescription drug pricing) H.R. 2471, the Consolidated Appropriations Act (340B provisions and potential drug pricing provisions) The FDA User Fee Reauthorizations (no bill numbers yet)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEANNE HAGGERTY New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.